Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 34Leukemia 26Lymphoma, Non-Hodgkin 23Lymphoma 22Precursor Cell Lymphoblastic Leukemia-Lymphoma 21Recurrence 19Leukemia, Lymphocytic, Chronic, B-Cell 19Myelodysplastic Syndromes 18Hematologic Neoplasms 18Melanoma 16Neoplasm Metastasis 15Lymphoma, B-Cell 14Multiple Myeloma 12Pancreatic Neoplasms 11Hodgkin Disease 11Stomach Neoplasms 10Ovarian Neoplasms 10Lymphoma, Large B-Cell, Diffuse 10Breast Neoplasms 9Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Lymphoma, Mantle-Cell 7Lymphoma, Follicular 7Uterine Cervical Neoplasms 6Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Triple Negative Breast Neoplasms 5Neoplasms, Plasma Cell 5Kidney Neoplasms 5Burkitt Lymphoma 5Myeloproliferative Disorders 4

Interventions

otelixizumab 1fludarabine phosphate 1fludarabine 1Metoprolol 1Interleukin 1 Receptor Antagonist Protein 1Infliximab 1Etanercept 1Cyclophosphamide 1AP 1903 reagent 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Cytokine Release Syndrome × fludarabine × Clear all
NCT03016377 2025-10-27

Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL

UNC Lineberger Comprehensive Cancer Center

Phase 1/2 Active not recruiting
17 enrolled
LymphoidOther hematologic neoplasm

Cytokine Release Syndrome, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡